BCL2 and small cell lung carcinoma: Therapeutic strategies against BCL-2 targets are equally promising, yet agents targeting BCL-2 such as Navitoclax exhibited merely limited activity in single-agent trials against advanced and relapsed SCLC, with considerable side effects observed in some patients89, 90.